Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3016797 | 0.78 | ADORA3 (0.35) | ADORA2AADORA2BADORA3ADORA1CSNK2A2 | |
| SCHEMBL4065388 | 0.74 | DGAT1 (0.38) | — | |
| SCHEMBL15740098 | 0.68 | MAPT (0.35) | — | |
| SCHEMBL12027350 | 0.67 | FLT4 (0.33) | — | |
| SCHEMBL12539835 | 0.66 | MEN1 (0.37) | ADORA2AADORA1 | |
| SCHEMBL23214023 | 0.64 | CYP1A2 (0.36) | ADORA2AADORA2B | |
| SCHEMBL13713523 | 0.64 | SMN1; SMN2 (0.34) | — | |
| SCHEMBL30053712 | 0.62 | FAAH (0.38) | — | |
| SCHEMBL23834461 | 0.62 | FAAH (0.38) | — | |
| SCHEMBL13713297 | 0.62 | HPGD (0.36) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2077268-A1 | Process for preparing inhibitors of nucleoside metabolism | Industrial Research Limited (NZ) | 2009-07-08 | — | — | EP | disclosed |
| EP-1165564-B1 | PROCESS FOR PREPARING INHIBITORS OF NUCLEOSIDE METABOLISM | IND RES LTD (NZ) | 2009-03-11 | — | — | EP | disclosed |
| US-7405297-B2 | Process for preparing inhibitors of nucleoside metabolism | INDUSTRIAL RESEARCH LIMITED (NZ) | 2008-07-29 | — | — | US | disclosed |
| US-20070161667-A1 | Process for preparing inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2007-07-12 | — | — | US | disclosed |
| US-7211677-B2 | Process for preparing inhibitors of nucleoside metabolism | INDUSTRIAL RESEARCH LIMITED (NZ) | 2007-05-01 | — | — | US | disclosed |
| US-20060089498-A1 | Process for preparing inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| US-7022852-B2 | Process for preparing inhibitors of nucleoside metabolism | INDUSTRIAL RESEARCH LIMITED (NZ) | 2006-04-04 | — | — | US | disclosed |
| US-20040181063-A1 | Process for preparing inhibitors of nucleoside metabolism | BIOCRYST PHARMACEUTICALS, INC. | 2004-09-16 | — | — | US | disclosed |
| US-6693193-B1 | COUPLING AN N- AND O-PROTECTED 2,3-DIHYDROXY-PYRROLIDINE TO THE 2-POSITION AND DEPROTECTING | INDUSTRIAL RESEARCH LIMITED (NZ) | 2004-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089498-A1 | Process for preparing inhibitors of nucleoside metabolism | UGT1A3, AGL, PNP | ADORA2A 1161/4885ADORA2B 803/4885ADORA3 219/4885 |
| US-20040181063-A1 | Process for preparing inhibitors of nucleoside metabolism | XDH, PNP, AGL | ADORA2A 853/4885ADORA2B 820/4885ADORA3 445/4885 |
| US-20070161667-A1 | Process for preparing inhibitors of nucleoside metabolism | PNP, UGT1A3, AGL | ADORA2A 1059/4885ADORA2B 704/4885ADORA3 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.